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Abstract Fat-1 transgenic mice, which endoge-
nously convert n-6 PUFA to n-3 PUFA, are a useful
tool in health research; however with this model
timing of n-3 PUFA enrichment cannot be directly
controlled. To add such capability, the novel Cre-
recombinase inducible fat-1 (iFat1) transgenic mouse
has been developed. The aim of this study was to
characterize the utility of the iFat1 transgene as a
model of Cre-inducible endogenous n-3 PUFA enrich-
ment. Functionality of the iFat1 transgene was
screened both in vitro and in vivo. In the presence of
Cre, the iFat1 transgene resulted in a balancing
(p\0.01) of the n-6/n-3 PUFA ratio within phospho-
lipids in the human embryonic kidney 293T cell line.
For in vivo analysis, iFat1 transgenic mice were
crossed with the R26-Cre-ER
T2 (Tam-Cre) mouse
line, a tamoxifen inducible Cre-expression model.
Tam-Cre/iFat1 doublehybridsweretransientlytreated
with tamoxifen at 6–7 weeks, then terminated
3 weeks later. Tamoxifen treated mice had increased
(p\0.05) tissue n-3 PUFA and Ctwo-fold reduction
(p\0.05) in the n-6/n-3 PUFA ratio of liver, kidney
and muscle phospholipids relative to vehicle treated
controls. Collectively these ﬁndings suggest that the
iFat1 transgenic mouse may be a promising tool to
help elucidate the temporal effects through which n-3
PUFA impacts health related outcomes.
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In recent years, dietary n-3 PUFA, particularly eico-
sapentaenoic acid (EPA) and docosahexaenoic acid
(DHA), have garnered strong research and public
interest due to their numerous reported beneﬁcial
health effects (Anderson and Ma 2009; Fetterman and
Zdanowicz 2009). However, there remain many
fundamental questions regarding their biological role
and mechanism of action. In particular, timing of
exposureduringthelifecycleisbecomingincreasingly
salient as a growing body of research suggests that the
origins of chronic disease begins in the early years of
life (Calkins and Devaskar 2011). No experimental
model currently exists which enables the precise study
of timing of exposure of n-3 PUFA. Thus, the
objective of this study was to develop an inducible
transgenic mouse model for the synthesis of n-3
PUFA.
In 2004, Kang and colleagues described the devel-
opment of the ﬁrst transgenic mouse model capable of
endogenous n-3 PUFA biosynthesis (Kang et al.
2004). Fat-1 transgenic mice are uniquely able to
convert n-6 PUFA to n-3 PUFA through constitutive
expression of the fat-1 transgene, an n-3 desaturase
native to the roundworm Caenorhabditis elegans (C.
elegans). By contrast, mammals lack this gene and are
thus unable to synthesize n-3 PUFA and must be
obtained through the diet. To date, this transgenic
mouse model has greatly enhanced our insight into the
protective effects of lifelong endogenous tissue n-3
PUFA enrichment on numerous health related out-
comes including, cancer chemoprevention, bone
development, inﬂammatory/immune pathology, and
neurological disease (Kang 2007; Lau et al. 2009a, b;
Lebbadi et al. 2011; MacLennan et al. 2013). How-
ever, while this well-controlled model is able to
minimize diet-based variability and confounding that
is inherent to traditional diet feeding approaches, n-3
PUFAenrichmentencompassesthefulldurationofthe
lifecycle,includingcriticalwindowsofdevelopmental
programming which are suggested to be highly
sensitive to n-3 PUFA (Calder et al. 2010; Hilakivi-
Clarke 2007; Luijten et al. 2013). As such, the ability
to more clearly deﬁne critical periods of development
during which n-3 PUFA can elicit health related
beneﬁts will greatly assist in reﬁning the therapeutic
applicability of this class of fatty acids.
The bacteriophage P1 derived Cre-loxP recombi-
nase system is a commonly employed approach to
achieve conditional mutagenesis within mammalian
cells (Nagy 2000). Through selective inclusion of a
loxP ﬂanked regulatory STOP element between a
transgene and its driving promoter, Cre-inducible
control over transgene activation can be successfully
achieved (Lakso et al. 1992). Moreover, since the Cre-
loxP recombination system require, at minimum, two
independent genetic components to produce condi-
tionality, ﬂoxed transgenic mice harbour a more
versatile research potential than that which is achiev-
able with more classical transgenic approaches. While
alternative murine models with both broad (Wei et al.
2010)andtissuespeciﬁc(Jietal.2009;Kaoetal.2006)
patterns of heterologous C. elegans fat-1 gene expres-
sion have been reported, a model capable of Cre-
inducible fat-1 expression has yet to be described. To
this end, we report the development and characteriza-
tion of a Cre-inducible fat-1 (iFat1) mouse model.
The iFat1 transgene consists of a loxP ﬂanked
STOP element positioned between the fat-1 coding
DNA sequence and its upstream CAG promoter, a
chicken b-actin/CMV immediate early enhancer
fusion promoter which has been demonstrated to drive
a strong ubiquitous pattern of transgene expression
in vivo (Okabe et al. 1997; Fig. 1). To protect against
uncontrolled transgene activation, the loxP ﬂanked
regulatory STOP sequence of the iFat1 transgene is
equipped with a C-terminal portion of the yeast HIS3
gene, an SV40 polyadenylation signal, false transla-
tional initiation codon 50 splice donor site. This
transcriptional/translational block, has been demon-
strated to prevent functional activation of downstream
transgenes with high efﬁciency in the absence of Cre
recombinase (Lakso et al. 1992). This study was
designed to evaluate the utility the iFat1 transgene as a
model of Cre-inducible fat-1 expression. Function of
the iFat1 transgene was screened in vitro using co-
transfection experiments in the HEK 293T cell line.
For in vivo characterization the Tam-Cre mouse line
was selected (Ventura et al. 2007). Tam-Cre mice
ubiquitously express a human estrogen receptor-Cre
fusion protein which is reliant on administration of the
drug tamoxifen for nuclear translocation and subse-
quent Cre-mediated recombination (Ventura et al.
2007). Using these complementary in vitro and in vivo
methodologies we describe, for the ﬁrst time, a novel
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PUFA enrichment.
Materials and methods
Transgenic construct and iFat1 model
development
The iFat1 transgenic construct and mouse model were
commercially generated (GenOway, Lyon, France).
The fat-1 cDNA, codon optimized for efﬁcient
mammalian expression were provided by Dr. Jing
Kang (Massachusetts General Hospital/Harvard Med-
ical School).
A validated Quick Knock-in
TM approach was used
to introduce a single copy of the iFat1 transgenic
cassette into the hypoxanthine phosphoribosyltransfer-
ase (Hprt) locus of the X-chromosome through homol-
ogousrecombinationinE14Tg2aembryonicstemcells,
a derivative of the 129P2/OlaHsd strain (Fig. 2). The
Hprt gene codes for a house keeping protein integral to
the Salvage Pathway of nucleotide synthesis, an
enzymatic cascade which is reliant on the recycled
degradation products of nucleotide metabolism as
substrate in the synthesis of purine nucleotides. In
E14Tg2a embryonic stem cells a 35 kb portion of the
Hprt locus encompassing the promoter and ﬁrst two
exons has been deleted rendering this cell line solely
dependent on the de novo pathway of nucleotide
synthesis for survival (Hooper et al. 1987). The iFat1
transgenic cassette was designed to simultaneously
restore Hprt gene function, through introduction of
Fig. 1 SchematicrepresentationoftheiFat1transgene.TheiFat1
transgenic construct consists of a loxP ﬂanked STOP cassette
positioned between the codon optimized fat-1 coding cDNA and
upstream ubiquitous CAG promoter. This transcriptional regula-
tory mechanism, with back-up translational block, has been
demonstrated to prevent functional activation of downstream
transgenes efﬁciency in the absence of Cre recombinase
Fig. 2 Construct map of
DMA1-HR the iFat-
1targeting vector (as
provided by manufacturer,
GenOway). A single copy of
the iFat-1 transgene was
speciﬁcally targeted to the
Hprt locus of the
X-chromosome using
GenOway’s validated Quick
Knock-in
TM approach
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123human equivalents of the missing gene region, and
insert the iFat1 transgene immediately upstream of this
locus. Correctly targeted E14Tg2a clones were there-
fore positively selected based on resistance to hypo-
xanthine, aminopterin and thymidine (HAT) medium,
which effectively blocks the de-novo pathway of
nucleotide synthesis. Targeted transgenesis through
restoration of Hprt function in E14Tg2a and E14Tg2a-
derivatives is a commonly used approach for the
generation of transgenic mouse lines (Bronson et al.
1996; Cvetkovic et al. 2000; Evans et al. 2000;I m r i e
et al. 2012).
The presence of successful recombination events in
HAT resistant E14Tg2a clones was validated by
southern blot analysis prior to generation of male
chimeras through C57BL/6 J blastocyst injection.
Highly chimeric males were bred with C57BL/6 J
females to generate F1 progeny. Germ-line transmis-
sionoftheiFat1transgenetoF1progenywasconﬁrmed
by PCR and southern blot analysis. The resultant iFat1
F1 female heterozygous progeny were subsequently
transferredfromGenOwaytotheUniversityofGuelph,
at which point a breeding colony of heterozygous
females was established. Since the iFat1 transgene is
X-linked, males cannot inherit this transgene from
paternal origins. The iFat1 breeding colony was
established and is maintained through backcrossing of
iFat1 heterozygous females with wildtype FC57BL/
6 N males (Charles River). This strategy ensures that a
subset of females and males within every generation
inherits the iFat1 transgene.
Plasmids
The DMA1-express plasmid (9771 bp), a conditional
expression vector containing the iFat1 transgenic con-
struct,wasobtainedfromGenOway(Lyon,France).All
other plasmids were obtained through the Addgene
plasmid repository (www.addgene.org), deposited by
Dr. Connie Cepko (Harvard Medical School). pCAG-
Cre (5871 bp) is a plasmid in which the Cre expression
is under direct control of the constitutively expressed
CAGpromoter(Addgeneplasmid13775)(Matsudaand
Cepko 2007) The backbone vector of pCAG-Cre,
pCAGEN (4798 bp), was used as a negative control
(Addgene plasmid 11160) (Matsuda and Cepko 2004).
All plasmids were puriﬁed using Wizard
 Plus Maxi-
preps DNA Puriﬁcation System (Promega, A7270).
Puriﬁed plasmid DNA was eluted in 1.5 mL DEPC
treated water and quantiﬁed via spectrophotometry
(ThermoScientiﬁc NanoDrop 2000).
Cell Culture and Co-transfection
Functionality of the iFat1 transgene were screened
in vitro via co-transfection experiments employing
HEK 293T cells and the transfecting agent polyethy-
lenimine(PEI)(SigmaAldrich408727),bothofwhich
were generously provided by Dr. Nina Jones (Depart-
ment ofMolecular and CellularBiology, Universityof
Guelph).
For routine maintenance, HEK 293T cells were
grown ina standard culture medium composedof high-
glucose DMEM (ThermoScientiﬁc SH30022.01), sup-
plemented with 10 % FBS (Sigma F1051) and 1 %
penicillin/streptomycin (Sigma A5955). For co-trans-
fection experiments, cells were seeded at a density of
approximately 0.5 9 10
6 cells per 10 cm culture plate.
The next day standard culture medium was aspirated
and replaced with 10 mL of freshly prepared 100 lM
linoleic acid (LA) supplemented DMEM containing
5 % FBS, 1 % penicillin/streptomycin and 0.1 % BSA
(Roche 10735078001), as substrate, for a period of
72 h. Twenty-four hours following initiation of fatty
acid treatment, cells were treated with either [a] trans-
fecting agent alone in the absence of plasmid DNA
[b] DMA1-express and pCAGEN (iFat1/Empty) or
[c] DMA1-express and pCAG-Cre (iFat1/Cre). For
each co-transfection reaction, 750 lLo fO p t i M E M
serum free medium (Invitrogen Gibco
 31985) and
25 lL of 2 mg/mL PEI were added to a total of 12 lg,
of equally balanced, plasmid DNA. The transfection
solution was brieﬂy vortexed then incubated at room
temperature for 5 min prior to edge-wise application to
cellplates. 48 hpost-transfectioncellswerepelletedby
centrifugation at 5009g for 5 min at 4 C. Supernatant
was discarded and samples were subsequently rinsed
twice in PBS by sequential re-suspension, centrifuga-
tion and supernatant disposal. Resulting cell pellets
were directly processed for lipid extraction.
Experimental animals
Male heterozygous Tam-Cre mice (Jackson Labora-
tories) were bred with female heterozygous iFat1
mice, which had been backcrossed onto a C57BL/6
background for 3 generations. Litters were weaned at
3 weeks of age, genotyped and male progeny
492 Transgenic Res (2014) 23:489–501
123identiﬁed as either: Tam-Cre
(-/-)/iFat1
(-) (WT),
Tam-Cre
(-/-)/iFat1
(?) (iFat1) and Tam-Cre
(?/-)/
iFat1
(?) (Tam-Cre/iFat1) were used for the purpose
of this study. Potential Cre-independent background
expression characteristics of the iFat1 transgene were
screened for using WT and iFat1 mice. For this, mice
were maintained on the experimental diet throughout
the study duration but received no additional treat-
ment. Conversely, the Cre-inducible activation proﬁle
of the iFat1 transgene was considered using Tam-Cre/
iFat1 double hybrid mice. Commencing at 6–7 weeks
of age, Tam-Cre/iFat1 double hybrids were treated
with either 100 lL of 10 mg/mL tamoxifen free-base
(Sigma Aldrich, T-5648) suspended in corn-oil
(Sigma C8267) or 100 lL of vehicle control, via one
daily intraperitoneal (IP) injection administered for a
course of ﬁve consecutive days.
Breeders and their progeny were maintained on a
specially formulated modiﬁed AIN-93G diet contain-
ing 10 % w/w safﬂower oil diet (Research Diets,
#D04092701), rich in LA. The fatty acid composition
of this experimental diet has been reported elsewhere
(MacLennan et al. 2013). Mice were housed 1–3/cage
in a temperature and humidity controlled room on a
diurnal 12 h light/dark cycle. In order to prevent
potential cross-contamination by coprophagy between
groups, mice were separately housed based on treat-
ment strategy/group(Brakeetal.2004).Allmice were
euthanizedat9–10 weeksofagebyCO2asphyxiation.
Kidney, liver, skeletal muscle and brain tissues were
immediately harvested, snap frozen in liquid nitrogen
and stored at -80 C for later analysis. The animal
utilization protocol for this study was approved by,
and conducted in accordance with, the University of
Guelph’s Animal Care Committee (protocol 12G002).
Genotyping by PCR
Brieﬂy, tail biopsies were incubated overnight, at
55 C, with proteinase K (Invitrogen 25530-015) and
tail lysis buffer (50 mM Tris, 100 mM NaCl, 1 %
sodium dodecyl sulphate and 25 mM EDTA). DNA
was extracted from digested tail samples with buffer
saturated phenol (Invitrogen Ultrapure
TM 15513-039),
precipitated via ethanol washing and re-suspended in
30 lL of Tris–EDTA buffer. For each sample, 0.5 lL
of genomic DNA was combined with 24.5 lL of PCR
master-mix solution and ampliﬁed using an Applied
Biosystems Veriti 96 Well Thermal Cycler. To screen
samples for presence of the Tam-Cre transgene, PCR
master mix was prepared to a ﬁnal concentration of
0.2 mM dNTP (ThermoScientiﬁc Fermentas R0192),
2 mM MgCl2 and 0.625 units Platinum
 Taq DNA
polymerase (Invitrogen 10966-034) and 0.5 lM each
of speciﬁed primers (Ventura et al. 2007). Samples
were incubated at 94 C for 180 s, followed by 35
cycles of 94 C for 30 s, 58 C for 90 s and 72 C for
60 s. Samples were held at a ﬁnal extension temper-
ature of 72 C for 300 s. For iFat1 reactions, PCR
master mix was composed of 0.3 mM dNTP,
109 PCR buffer, 1.5 mM MgCl2 and 1.5 units of
Platinum
 Taq and 0.4 lM each of: 50-ACGTCA
GTAGTCATAGGAACTGCGGTCG-30(F) and 50-C
CAACCGGTGGGACATTT GAGTTG-30(R). Sam-
ples were incubated at94 Cfor 120 s, followed by 35
cycles of 94 C for 30 s, 55 C for 30 s and 68 C for
Fig. 3 Representative gas chromatography trace of PE fraction
of co-transfected HEK 293T cells. In relation to cells co-
transfected with (a) iFat1/Empty, co-transfection with (b)i F a t - 1 /
Cre resulted in marked elevations in n-3 PUFA and corresponding
reductions in n-6 PUFA species. For detailed PUFA composi-
tional changes within phospholipid fractions refer to Table 1
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12360 s. Samples were held at a ﬁnal extension temper-
ature of 68 C for 420 s. This protocol ampliﬁes a
325 bp sequence of the iFat1 transgene.
Ampliﬁed DNA was loaded on a 2 % agarose gel
containing ethidium bromide (Fisher Scientiﬁc BP1302-
10) and separated via gel electrophoresis. Gels were
imaged under UV light using the FluorChem HD2
imaging system.
Tamoxifen Preparation
A stock solution of 10 mg/mL tamoxifen free-base
solubilized in ethanol/corn-oil was freshly prepared
immediately before initiation of tamoxifen treatment
and stored, protected from light, at 4 C for the
durationofthe5 dayinductionperiod.Brieﬂy,100 lL
of anhydrous ethanol was added to a 10 mg aliquot of
tamoxifen free-base and heated at 55 C on dry heat-
block with frequent intermittent vortexing to facilitate
tamoxifen dissolution. 900 lL of sterile corn-oil was
added and the solution was sonicated to homogeneity
(30 s). Vehicle control was prepared in an analogous
fashion, through omission of tamoxifen from the
protocol.
Lipid extraction
Total lipids were extracted from both cell culture and
tissues using a modiﬁed method of Folch et al. (1957).
For in vitro analysis, cell pellets were suspended in
1 mL of 0.1 M potassium chloride and immediately
transferred into pre-chilled acid washed tubes. A 2:1
mixture of chloroform (Fisher Scientiﬁc C298-4):
methanol (Fisher Scientiﬁc A452-4) was freshly
preparedand 4 mLwas added to each sample. Samples
werevortexedfor1 min,ﬂushedwithagentlestreamof
nitrogen gas and incubated at 4 C overnight. Samples
were centrifuged at 3409g for 10 min to separate
phases. The lipid-containing chloroform layer was
transferred into a disposable glass culture tube.
Extracted lipids were dried under a gentle stream of
nitrogen and reconstituted in 100 lL of chloroform for
subsequent fatty acid analysis. For in vivo analysis,
total lipids were extracted from 50 to 100 mg tissue
sections. Brieﬂy, tissue samples were homogenized on
ice in 2.5 mL of 0.1 M potassium chloride (Fisher
PowerGen 125) and subsequently prepared for lipid
extraction using equivalent ﬁnal solvent concentrations
and extractionproceduresasoutlined above. Following
Table 1 Fatty acid composition (% total) of phosphatidylethanolamine (PE) and phosphatidylcholine (PC) in co-transfected HEK
293T cells
Fatty acid PE PC
No DNA iFat1/Empty iFat1/Cre No DNA iFat1/Empty iFat1/Cre
18:2n-6 29.1 ± 2.7
a 31.4 ± 2.4
a 16.3 ± 2.0
b 34.4 ± 2.2
a 32.6 ± 3.9
a 13.9 ± 2.1
b
20:4n-6 4.8 ± 0.9
a 5.4 ± 0.4
a 1.9 ± 0.2
b 0.7 ± 0.1
a 0.6 ± 0.0
a trace
b
22:4n-6 3.3 ± 0.6
a 4.5 ± 0.6
a 2.0 ± 0.3
b 0.3 ± 0.3 0.4 ± 0.1 0.2 ± 0.3
22:5n-6 n.d. n.d. n.d. n.d. n.d. n.d.
18:3n-3 n.d.
b 0.2 ± 0.4
b 15.0 ± 0.5
a n.d.
c 0.2 ± 0.1
b 18.7 ± 0.6
a
20:5n-3 n.d.
b n.d.
b 2.6 ± 0.3
a n.d.
b n.d.
b 0.5 ± 0.0
a
22:5n-3 1.8 ± 0.1
b 2.2 ± 0.3
b 4.5 ± 0.5
a 0.4 ± 0.2 0.5 ± 0.2 0.7 ± 0.0
22:6n-3 1.9 ± 0.6 1.9 ± 0.3 1.8 ± 0.3 trace 0.4 ± 0.1 0.4 ± 0.0
Total n-6 43.9 ± 4.5
a 48.3 ± 2.0
a 25.0 ± 2.3
b 40.0 ± 2.1
a 37.9 ± 4.2
a 16.7 ± 2.5
b
Total n-3 3.7 ± 0.5
b 4.3 ± 0.9
b 26.0 ± 0.5
a 0.5 ± 0.1
b 1.1 ± 0.3
b 22.2 ± 0.6
a
n-6/n-3 11.8 ± 0.6
a 11.7 ± 2.9
a 1.0 ± 0.1
b 83.9 ± 15.1
a 37.5 ± 14.5
b 0.8 ± 0.1
c
Total SFA 38.7 ± 8.7 33.1 ± 1.3 33.6 ± 2.1 47.0 ± 1.1 49.7 ± 3.9 48.7 ± 1.4
Total MUFA 13.5 ± 3.7 13.8 ± 0.3 15.1 ± 1.6 12.4 ± 3.0 10.9 ± 0.4 12.1 ± 1.7
Total PUFA 47.8 ± 5.1 53.1 ± 1.2 51.3 ± 2.4 40.6 ± 2.2 39.4 ± 4.0 39.2 ± 3.1
Cells were co-transfected with iFat1/Empty or iFat1/Cre. Cells treated with transfecting reagent in the absence of plasmid DNA (No
DNA) were also included as controls for potential background difference in fatty acid composition attributable to Cre-independent
expression of the iFat1 transgene. For each phospholipid fraction, means possessing different superscripts within rows denote
signiﬁcant differences between groups (p\0.05)
494 Transgenic Res (2014) 23:489–501
123centrifugation,thechloroformlayerofeachsamplewas
transferred to a corresponding pre-weighed acid
washed tube, dried under a gentle stream of nitrogen
and reconstituted at a concentration of 10 mg/mL in
chloroform.
Fatty acid analysis
Phosphatidylethanolamine (PE), phosphatidylcholine
(PC), phosphatidylserine (PS) and phosphatidylinositol
(PI) fractions were isolated from total lipid extracts by
thin layer chromatography using silica H-plates (VWR
5721-7) as previously outlined (5). Fatty acid methyl
esters were prepared by incubating in 2 mL of hexane
(EMD HX0295-1) and 2 mL 14 % boron triﬂuoride-
methanolsolution(SigmaAldrichB1252)at100 Cfor
90 min. 2 mL of double deionized water was added to
each tube to stop the methylation reaction. Samples
were vortexed and phases were separated via centrifu-
gation at 3409g for 10 min. The upper hexane layer
was transferred to a 2 mL glass vial (Agilent
5182-0714), dried under a gentle stream of nitrogen
gas and reconstituted in hexane for analysis by gas–
liquid chromatography.
Fatty acid methyl ester composition of phospholipid
fractions was resolved using an Agilent 7890A gas
chromatograph (Agilent Technologies, Santa Clara
USA) equipped with a ﬂame ionization detector and a
fused-silica polyethylene glycol capillary column (DB-
FFAP; 15 m, 0.1 mm internal diameter, 0.1 lmﬁ l m
thickness, Agilent Technologies 127-32H2). Samples
were injected in split mode (1:200) using hydrogen as
the carriergas (30 mL/min)and eluted according tothe
following temperature program: 150 C for 20 s, ramp
at 35 C/min, hold at 170 C for 3 min, ramp at
9 C/min, hold at 225 C for 30 s, ramp at 80 C/min,
hold at 245 C for 2.2 min. Chromatograms were
generated using the Agilent EZChrom Elite GC Data
System (version 3.3.2). Individual fatty acid peak
identities were veriﬁed by comparison with peak
retention times of known fatty acid standards (Nu-
Check Prep, Elysian, MN), and expressed as relative
percent composition of total fatty acids.
Statistical analysis
All fatty acid data is expressed as mean ± standard
deviation(SD).Statisticalanalysiswasconductedusing
SASv9.1.ANOVAwithTukeyposthoctestwasusedto
analyzefattyaciddatafrominvitroexperiments.Where
appropriate, data was logarithmically transformed to
produce normality. Fatty acid data from in vivo exper-
iments were analyzed by using Student’s t tests. Signif-
icance was set at p\0.05 for all analyses.
Results
The iFat1 transgene permits conditional n-3 PUFA
enrichment in vitro
In comparison to controls, iFat1/Cre co-transfected
cells were observed to have pronounced alterations in
n-3 and n-6 PUFA composition within membrane
phospholipids. PUFA were selectively and differen-
tially enriched in phospholipids. The PUFA compo-
sitional changes in HEK 293T cells were most marked
within the PE and PC fractions. A representative
Fig. 4 Transcriptional expression characteristics of the iFat-1
transgene in vitro. Cells were co-transfected with iFat-1/Emp or
iFat-1/Cre and harvested for total cellular RNA 24 h post-
transfection. RT-PCR was performed to probe for the presence
of transcripts corresponding to the fat-1 coding sequence.
Hepatic cDNA obtained from total hepatic RNA of a
constitutive fat-1 mouse was included as a reference (?)
control. RT-PCR for rig/S15 cDNA, a constitutively expressed
housekeeping gene encoding a small ribosomal subunit protein,
was included as an indirect marker of RNA quality for each
sample as per manufacturer instructions (RNAqueous
- 4PCR
kit). Results demonstrate the presence of Cre-independent
expression from the iFat-1 transgene
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123chromatographic trace from the PE fraction of co-
transfected cells is shown in Fig. 3 and details on the
compositional changes of n-6 and n-3 PUFA species
withinthePEandPCfractions arereportedinTable 1.
Within the PE and PC fractions, a-linolenic acid
(ALA) (p\0.01) and LA (p\0.01) were most
notably enriched and reduced, respectively. However,
signiﬁcantincreasesinseveraldownstreamlong-chain
n-3 PUFA species, including EPA (p\0.05) and
22:5n-3 (p\0.01), with concomitant decreases in
corresponding n-6 PUFA species including 20:4n-6
and 22:4n-6 (p\0.01) were also evident. Collec-
tively, the observed changes in fatty acid composition
within the PE fraction was consistent with a balancing
of the n-6/n-3 PUFA ratio (1.0, p\0.01) in iFat1/Cre
treated cells relative to controls. Results from other
phospholipid fractions werein general agreement with
those of the PE and PC fractions. Total saturated fatty
acids (SFA), monounsaturated fatty acids (MUFA)
and PUFA did not differ between experimental groups
for any phospholipid fraction. It was observed that
background Cre-independent mRNA expression from
the iFat1 transgene was detected by RT-PCR (Fig. 4),
however this did not correspond to changes in fatty
acid composition. Total n-6 PUFA content (PE, PC)
and total n-3 PUFA content (PE, PC) did not
signiﬁcantly differ between cells co-transfected with
iFat1/Empty and control cells which had been treated
with transfecting reagent alone (No DNA). Addition-
ally, iFat1/Empty and transfection controls were
demonstrated to possess comparable fatty acid com-
position for all individual PUFA species measured.
Thus, these ﬁndings indicate that while the loxP
ﬂanked STOP cassette of the iFat1 transgene may not
terminate transcription with 100 % efﬁciency, its
translation block mechanism is sufﬁcient to render
PUFA phenotype strictly reliant on Cre as an activat-
ing factor.
The iFat1 Transgene permits conditional n-3
PUFA enrichment in vivo
Analogous to the in vitro results, background Cre-
independent mRNA expression of fat-1 associated
transcripts was detected within the hepatic tissue of
mice carrying the iFat1 transgene (data not shown).
However, the PUFA phenotype of liver tissue from
WT and iFat1 (non treated) transgenic mice was
similar (Table 2). The PUFA composition of kidney,
muscle and brain phospholipids between WT and
iFat1 transgenic mice were also closely matched (data
not shown).
Table 2 Non-induced iFat1 mouse hepatic fatty acid composition
Fatty acid PE PC
WT iFat1 WT iFat1
18:2n-6 8.2 ± 0.7 6.6 ± 0.9 16.8 ± 1.5 19.3 ± 1.7
20:4n-6 30.7 ± 0.8 30.2 ± 0.7 n.d. n.d.
22:4n-6 1.3 ± 0.1 1.4 ± 0.2 20.8 ± 2.5 22.7 ± 1.0
22:5n-6 7.5 ± 1.0 8.0 ± 1.3 n.d. n.d.
18:3n-3 n.d. n.d. 0.5 ± 0.1 0.6 ± 0.1
20:5n-3 n.d. n.d. 4.3 ± 0.7 4.2 ± 0.7
22:5n-3 0.2 ± 0.1 trace trace trace
22:6n-3 2.2 ± 0.5 1.8 ± 0.1 0.9 ± 0.1 1.1 ± 0.2
Sum of n-6 49.6 ± 0.7 47.9 ± 1.1 49.6 ± 0.8* 45.7 ± 2.2
Sum of n-3 2.4 ± 0.5 2.0 ± 0.2 1.2 ± 0.2 1.0 ± 0.2
n-6/n-3 21.8 ± 5.7 24.8 ± 3.0 44.4 ± 10.7 47.5 ± 8.8
Total SFA 37.6 ± 0.8 38.9 ± 2.1 40.7 ± 0.6 42.1 ± 1.9
Total MUFA 10.4 ± 0.6 11.3 ± 1.4 8.5 ± 0.3 11.2 ± 2.2
Total PUFA 52.0 ± 0.5* 49.9 ± 1.1 50.7 ± 0.8* 46.7 ± 2.3
Phospholipid composition of select n-6 and n-3 PUFA in liver tissue from WT (n = 3/group) and iFat1 (n = 3/group): PE and PC.
Results expressed as mean ± SD. For each phospholipid fraction, means possessing asterisk (*) within rows indicate signiﬁcant
differences between groups
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123Conditional expression characteristics of the iFat1
transgene were assessed using tamoxifen treated and
vehicle treated Tam-Cre/iFat1 transgenic mice. The
composition of major n-6 and n-3 PUFA within the PE
and PC fraction of liver tissue are presented in Fig. 5
and detailed PUFA compositional data from each of
these major phospholipid fractions are provided in
Tables 3 and 4 respectively. In relation to vehicle
treated controls, tamoxifen treatment of Tam-Cre/
iFat1 mice resulted in relative enrichment in phospho-
lipid total n-3 PUFA in each of the liver (PE, PC;
p\0.01), kidney (PE and PC; p\0.01) and muscle
(PE; p\0.01, PC; p\0.05). Within all of these
tissue phospholipid fractions, DHA was the predom-
inant n-3 PUFA species enriched. However lesser
contributions to total relative n-3 PUFA enrichment
from 22:5n-3 within the liver (PE and PC; p\0.05),
kidney (PC; p\0.01, PE; p B 0.05) and muscle (PE
and PC; p\0.01) were also observed. Moreover,
relative reductions within the corresponding n-6
PUFA species, 22:5n-6 and 22:4n-6 were also
observed within select phospholipid fractions from
the liver and kidney as well as a small but signiﬁcant
overall decrease in total n-6 PUFA content in kidney
and muscle tissue. Collectively, these PUFA compo-
sitional changes resulted in an approximate twofold
reduction, or more, of the n-6/n-3 PUFA ratio in each
of the liver (PE: -3.6; p\0.01, PC: -2.3), kidney
(PE: -2.4 and PC: -2.4; p\0.01) and muscle
(PE: -2.0 and PC: -1.9; p\0.05) tissues. However,
PUFA compositional changes within the brain tissue
were less discernible, with only a small but signiﬁcant
difference in the n-6/n-3 PUFA ratio evident within
the PC fraction (-1.3 fold; p\0.05), which was
neitherassociatedwithamarkeddifferenceintotaln-6
PUFA or total n-3 PUFA between tamoxifen and
vehicle treated mice. Total SFA, MUFA and PUFA
did not generally differ between experimental groups.
Discussion
While research employing the fat-1 transgenic mouse
has lent strong support to the protective health beneﬁts
of lifelong n-3 PUFA exposure, the constitutive nature
of transgene expression precludes the application of
this model for investigating issues of timing of n-3
PUFA exposure. The iFat1 transgenic mouse, which
carries a Cre-inducible version of the C. elegans fat-1
gene has been developed as a potential tool to address
this research gap. In contrast to the original fat-1
transgene described by Kang et al. (2004), the iFat1
regulatory unit has been adapted to contain a ﬂoxed
STOP cassette, thus introducing an overarching mech-
anism through which the timing and/or pattern of
endogenous n-3 PUFA enrichment can be differen-
tially controlled. This study describes the novel iFat1
model containing a transgene capable of facilitating
Cre-inducible synthesis of endogenous n-3 PUFA
enrichment within mammalian cells and tissues.
The capacity of mammalian cells to endogenously
convert n-6 PUFA to n-3 PUFA through heterologous
expressionofthehumanizedC.elegansfat-1genewas
ﬁrst reported byKangetal.(2001).Inthis earlyreport,
an adenovirus mediated approach was used to specif-
ically introduce the fat-1 gene into cultured rat cardiac
myocytes, the net result of which was a balanced n-6/
n-3 PUFA ratio in total cellular lipids within a 48 h
period; an *15 fold reduction from that of controls
(Kang et al. 2001). This balancing effect has been
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Fig. 5 Relative fatty acid composition of major n-6 and n-3
PUFA species in the (A) PE and (B) PC fraction of liver tissue
from Tam-Cre/iFat1 mice treated with vehicle or tamoxifen
(Tam ?). Results expressed as mean ± SD (n = 3/group).
Asterisk denotes signiﬁcant difference (p\0.05) between
groups by Student’s t test
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123subsequently paralleled in various other mammalian
cell-lines of both murine (An et al. 2012; Ge et al.
2002b) and human origin (Ge et al. 2002a; Xia et al.
2005). Within the present study, simultaneous intro-
duction of iFat1 and Cre into HEK 293T cells was
associated with a complete balancing of the n-6/n-3
PUFA ratio of membrane phospholipids. This balanc-
ingeffect was directlyattributable toanincreasein the
relative proportion of n-3 PUFA at the expense of
corresponding n-6 PUFA species evident within all
major phospholipid fractions, though most pro-
nounced within PE (p\0.01) and PC (p\0.01)
phospholipids. Surprisingly, DHA was not enriched.
However, it is likely that additional incubation time
was needed to allow for further elongation and
desaturation from ALA given that downstream fatty
acids were not enriched to the same extent as ALA,
which is a direct product of desaturation of LA by the
FAT-1 protein. Collectively, these results indicate that
the iFat1 transgene is capable of producing Cre-
inducible regulation over endogenous n-3 PUFA
enrichment within mammalian cells in a manner that
is generally consistent with the original fat-1
construct.
Inextensiontotheinvitrostudyarmwhichvalidated
Cre-inducibility, the next phase of work was to
demonstrate temporal inducibility and functionality of
the model in an in vivo system. Tamoxifen dependent
recombinase systems, such as the Tam-Cre mouse
model is used widely, thus selected to validate the
in vivo utility of the iFat1 transgene. Indeed, within
3 weeks of iFat1 transgene induction the phospholipid
n-6/n-3 PUFA ratio of liver, kidney and muscle was
observed to be approximately twofold lower than that
of corresponding tissues taken from vehicle treated
controls. While the observed percent composition of
n-3 PUFA enrichment within the Cre-induced Tam-
Cre/iFat-1 mice appears lower than that previously
Table 3 Cre-inducible iFat1 expression characteristics in vivo: PE fraction
FA Liver Kidney Muscle Brain
Vehicle Tam? Vehicle Tam? Vehicle Tam? Vehicle Tam?
18:2n6 6.9 ± 2.8 9.1 ± 1.3 4.9 ± 1.0 5.0 ± 0.5 7.5 ± 0.4 7.5 ± 0.6 0.4 ± 0.0 0.4 ± 0.1
18:3n6 trace trace n.d. n.d. n.d. n.d. n.d. n.d.
20:2n6 0.5 ± 0.1 0.5 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.5 ± 0.1 0.3 ± 0.0 0.3 ± 0.1
20:3n6 1.0 ± 0.1 0.8 ± 0.0 0.6 ± 0.0 0.5 ± 0.1 0.7 ± 0.0 0.6 ± 0.1 0.5 ± 0.0 0.4 ± 0.0
20:4n6 30.3 ± 0.5 30.1 ± 0.4 32.9 ± 1.2 34.8 ± 2.0 13.6 ± 1.5 13.1 ± 0.7 15.3 ± 0.6 16.7 ± 0.2*
22:2n6 trace n.d. n.d. n.d. n.d. n.d. n.d. trace
22:4n6 1.3 ± 0.1* 1.1 ± 0.1 2.2 ± 0.3 1.8 ± 0.1 6.3 ± 0.3 6.9 ± 0.2 6.8 ± 0.1 6.9 ± 0.2
22:5n6 7.4 ± 1.5* 3.5 ± 0.5 11.2 ± 1.6* 6.0 ± 1.2 25.5 ± 2.4 22.1 ± 2.9 17.0 ± 0.3 15.2 ± 2.3
18:3n3 n.d. n.d. n.d. n.d. trace n.d. trace n.d.
18:4n3 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
20:3n3 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
20:5n3 n.d. n.d. n.d. n.d. n.d. 0.5 ± 0.2 n.d. n.d.
22:3n3 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
22:5n3 trace 0.4 ± 0.1* 0.2 ± 0.0 0.7 ± 0.2 0.6 ± 0.1 1.4 ± 0.2* 0.2 ± 0.0 0.3 ± 0.0
22:6n3 2.1 ± 0.3 6.8 ± 0.9* 3.5 ± 0.2 7.8 ± 1.5* 2.8 ± 0.3 4.6 ± 0.5* 10.0 ± 0.9 13.2 ± 3.6
Total n-6 PUFA 47.7 ± 0.9 45.2 ± 1.8 52.2 ± 0.4* 48.5 ± 0.8 53.9 ± 0.7* 50.7 ± 1.6 40.2 ± 0.6 40.0 ± 2.3
Total n-3 PUFA 2.2 ± 0.4 7.3 ± 1.0* 3.7 ± 0.2 8.5 ± 1.4* 3.5 ± 0.4 6.4 ± 0.9* 10.3 ± 0.9 13.5 ± 3.5
n-6/n-3 PUFA 22.2 ± 4.6* 6.3 ± 1.1 14.0 ± 1.0* 5.8 ± 0.8 15.6 ± 2.0* 8.0 ± 1.4 3.9 ± 0.3 3.1 ± 0.9
Total SFA 40.0 ± 1.3 39.3 ± 1.3 33.1 ± 0.2 32.2 ± 1.2 35.1 ± 0.9 35.6 ± 0.5 33.6 ± 1.4 32.9 ± 2.1
Total MUFA 10.2 ± 0.7* 8.3 ± 0.4 10.9 ± 0.2 10.7 ± 1.0 7.4 ± 1.0 7.2 ± 0.5 15.9 ± 1.8 13.5 ± 1.3
Total PUFA 49.9 ± 0.8 52.4 ± 1.4 56.0 ± 0.2 57.0 ± 2.1 57.5 ± 0.6 57.1 ± 1.0 50.5 ± 1.3 53.6 ± 1.3*
Relative PUFA composition within PE fraction of tissues from Tam-Cre/iFat1 mice treated with corn-oil (Vehicle) or tamoxifen
(Tam ?). Results expressed as mean ± SD (n = 3/group). Asterisk (*) denotes signiﬁcant difference (p\0.05) between groups by
Student’s t test
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123reported with the constitutive fat-1 model (Boudrault
et al. 2010;K a n ge ta l .2004; Smith et al. 2010;S u n
et al. 2011) and further substantiated within our lab
using age-matched fat-1 reference controls (data not
shown), it is not unexpected given that tissues were
examined 3 weeks post transgene induction, as com-
pared to constitutive expression. Interestingly, despite
clear evidencesupportingthe ability ofthe iFat1 mouse
model to facilitate Cre-induciblen-3 PUFA enrichment
within peripheral tissues, brain PUFA composition was
notfoundtomarkedly differbetweentamoxifentreated
Tam-Cre/iFat1 mice and vehicle treated controls.
However, a similar lack of brain phenotype has also
been previously reported in combination with the Tam-
Cremodelemployedwithinthepresentstudyaswellas
other ROSA26 promoter driven tamoxifen inducible
Cre lines. It is speculated to be the function of reduced
tamoxifen tissues access arising from the blood–brain-
barrier and/or low ROSA26 driven Cre expression
within brain tissue (Hameyer et al. 2007; Ripoche et al.
2013; Seibler et al. 2003). Further reﬁnement of the
Tamoxifen induction in terms of dosage, duration and
timing of exposure may also yield further enhance-
ments in tissue n-3 PUFA.
Inconclusion,thisstudyprovidesinvitroandinvivo
evidence that mammalian cells and tissues can be
modiﬁed through incorporation of the iFat1 transgene
to endogenously convert n-6 to n-3 PUFA in a manner
which is reliant on Cre as an activating factor. These
models have potential application as versatile tools in
addressing the temporal and/or tissue speciﬁc effects of
n-3 PUFA in disease prevention and treatment when
combined with other Cre expressing models.
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